Corvex Management
Corvex Management, LP is an investment firm headquartered in New York, New York that engages in value‐based investing across the capital structure in situations with identifiable catalysts. Corvex was founded in March 2011 and follows an opportunistic approach to investing with a specific focus on equity investments, special situations and distressed securities largely in North America.
View Older Stories View More Recent Stories
-
Form SC 13D/A MDU RESOURCES GROUP INC Filed by: Corvex Management LP
-
Form 13F-HR Corvex Management LP For: Dec 31
-
Form 3 GeneDx Holdings Corp. For: Jan 31 Filed by: Corvex Management LP
-
Form SC 13D/A MDU RESOURCES GROUP INC Filed by: Corvex Management LP
-
MDU Resources Group (MDU) Enters Cooperation Agreement With Corvex Management
-
MDU Resources Enters Into Cooperation Agreement With Corvex Management
-
Kindred's Nomination Committee proposes five new members to the Board of Directors
-
Form 13F-HR Corvex Management LP For: Sep 30
-
Form SC 13D/A MDU RESOURCES GROUP INC Filed by: Corvex Management LP
-
Notice to Extraordinary General Meeting of Kindred Group plc
-
Nomination Committee ahead of Kindred's 2023 Annual General Meeting
-
Form 13F-HR Corvex Management LP For: Jun 30
-
Notification of major holdings in Kindred Group plc
-
Corvex Management Advises Kindred Group PLC of 15% Ownership and Plan to Participate on Nomination Committee
-
U.S. utility MDU Resources backs its strategy after Meister's Corvex takes stake
-
Form SC 13D MDU RESOURCES GROUP INC Filed by: Corvex Management LP
-
Form 13F-HR Corvex Management LP For: Mar 31
-
Response to Corvex Management's statement
-
Kindred shareholder urges Swedish gaming group to consider sale
-
Corvex Statement on Kindred Group Investment
-
Notification of major holdings in Kindred Group plc
-
Form SC 13D/A Anaplan, Inc. Filed by: Corvex Management LP
-
Form SC 13D/A Anaplan, Inc. Filed by: Corvex Management LP
-
Form 13F-HR/A Corvex Management LP For: Dec 31
-
Form SC 13D Anaplan, Inc. Filed by: Corvex Management LP
-
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
-
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
-
Notification of major holdings in Kindred Group plc
-
Form 13F-HR Corvex Management LP For: Dec 31
-
MGM Resorts (MGM) And IAC (IAC) Announce Agreement To Purchase 9M Shares Of MGM Resorts Common Stock From Corvex Management Lp
-
MGM RESORTS INTERNATIONAL AND IAC ANNOUNCE AGREEMENT TO PURCHASE 9M SHARES OF MGM RESORTS COMMON STOCK FROM CORVEX MANAGEMENT LP
-
EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices
-
EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices
-
Centene settles with activist Politan, overhauls board, CEO to exit
-
EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination
-
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference
-
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa
-
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
-
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series
-
Form 13F-HR Corvex Management LP For: Sep 30
-
EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs
-
Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Ca
-
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
-
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
-
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
-
EQRx Appoints Kathy Giusti to Board of Directors
-
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
-
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
-
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
-
SomaLogic Closes Business Combination and Will Begin Trading Under the Ticker “SLGC” on the Nasdaq Stock Exchange

